Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $152 Price Target
Benzinga · 09/15 12:36
Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $152 price target.